Abstract Number: 283 • 2019 ACR/ARP Annual Meeting
Can Synovial Hypertrophy in the Feet Without Doppler Change During Treatment – Results from a Longitudinal Study of Rheumatoid Arthritis Patients Initiating Biological DMARD
Background/Purpose: Ultrasound is used to assess disease activity in rheumatoid arthritis (RA). Gray scale (GS) ultrasound shows the synovial hypertrophy (SH) and Doppler the amount…Abstract Number: 448 • 2019 ACR/ARP Annual Meeting
Central Sensitization in Patients with Rheumatoid Arthritis Using the Central Sensitization Inventory
Background/Purpose: Pain of rheumatoid arthritis (RA) is thought to be nociceptive. However, recent studies indicate that RA pain also includes the mechanism of central sensitization…Abstract Number: 474 • 2019 ACR/ARP Annual Meeting
Associations of Plasma Extravesicular (EV) MicroRNA Levels in Seropositive and Seronegative Rheumatoid Arthritis (RA)
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) are biomarkers that allow early diagnosis of RA in seropositive (ACPA+ or RF+) patients. However, some…Abstract Number: 525 • 2019 ACR/ARP Annual Meeting
Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis
Background/Purpose: Persistent drug-free remission of RA is a condition close to “cure” of the disease. Long-term drug-free remission is considered rare and challenging to reach,…Abstract Number: 820 • 2019 ACR/ARP Annual Meeting
Diurnal Stability of Transcriptional Profiles in Rheumatoid Arthritis
Background/Purpose: Our understanding of disease pathogenesis in Rheumatoid Arthritis (RA) is rapidly expanding with the advent of ‘Omics’ techniques. Importantly, current analysis takes into account…Abstract Number: 927 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results
Background/Purpose: Filgotinib (FIL), an orally administered, potent, selective inhibitor of Janus kinase 1 (JAK1), has shown good efficacy and was well tolerated for treatment of…Abstract Number: 1135 • 2019 ACR/ARP Annual Meeting
Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
Background/Purpose: Flares in rheumatoid arthritis (RA) are common. The shortage of readily available specialized care may hinder early detection and timely management of RA flares.…Abstract Number: 1336 • 2019 ACR/ARP Annual Meeting
Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis
Background/Purpose: Biologic (b) and targeted synthetic (ts) DMARDs have demonstrated efficacy for the treatment of rheumatoid arthritis (RA) in clinical trials; however, real-world evidence on…Abstract Number: 1364 • 2019 ACR/ARP Annual Meeting
Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients
Background/Purpose: The goal for treatment of RA is to obtain low disease activity for better outcomes. In order to achieve low disease activity, it is…Abstract Number: 1393 • 2019 ACR/ARP Annual Meeting
Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies
Background/Purpose: Pain, a core-set domain and a troubling symptom to patients with RA, may be directly related to inflammation. Unacceptable pain (UP) levels may persist…Abstract Number: 1428 • 2019 ACR/ARP Annual Meeting
Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug which can be used as an alternative to biologic disease modifying antirheumatic drugs (bDMARDs) for rheumatoid…Abstract Number: 1876 • 2019 ACR/ARP Annual Meeting
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
Background/Purpose: Denosumab, a monoclonal antibody against RANKL, is approved for the treatment of glucocorticoid (GC) induced osteoporosis (GiOP). In postmenopausal women with osteoporosis, denosumab discontinuation…Abstract Number: 1960 • 2019 ACR/ARP Annual Meeting
Pleiotropy of Genetic Predisposition to Rheumatoid Arthritis Increases the Risk for Autoimmune Disease
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that is associated with increased risk of cardiovascular disease, cardiometabolic disorders, and autoimmune disease. Thus, we…Abstract Number: 2096 • 2019 ACR/ARP Annual Meeting
An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients
Background/Purpose: Annual vaccination with inactivated influenza vaccine is recommended for adults with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Despite this, influenza immunization coverage…Abstract Number: 2261 • 2019 ACR/ARP Annual Meeting
Post Traumatic Stress Disorder in Patients with Rheumatoid Arthritis
Background/Purpose: There is growing evidence that complex interactions between individual's genetic susceptibility, immunological processes, and environmental factors such as stress , increase the risk of…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 56
- Next Page »